



(51) International Patent Classification:

C07D 311/80 (2006.01) *A61P 25/28* (2006.01)
A61K 31/352 (2006.01)

(21) International Application Number:

PCT/TR2014/000028

(22) International Filing Date:

6 February 2014 (06.02.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2013/02067 21 February 2013 (21.02.2013) TR

(71) Applicant: FARGEM FARMASÖTİK ARAŞTIRMA
GELİŞTİRME MERKEZİ SANAYİİ VE TİCARET
A.Ş. [TR/TR]; Sancaklar, 81100 Duzce (TR).

(72) Inventors; and

(71) Applicants (for US only): UNLU, Serdar [TR/TR]; Sancaklar, 81100 Duzce (TR). ESIRINGU, Ilker [TR/TR]; Sancaklar, 81100 Duzce (TR). SAHIN, Yasemin [TR/TR]; Sancaklar, 81100 Duzce (TR). ERCETIN, Tugba [TR/TR]; Sancaklar, 81100 Duzce (TR). OZ, Demet [TR/TR]; Sancaklar, 81100 Duzce (TR). SAHIN, Fethi [TR/TR]; Sancaklar, 81100 Duzce (TR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))

(54) Title: 1 -(DIMETHYLAMINO)ETHYL-SUBSTITUTED 6H-BENZO[C]CHROMEN-6-ONES AGAINST SENILE DEMENTIA

(57) Abstract: This invention relates to novel (±)1-(Dimethylamino)ethyl substituted 6H-benzo[c]chromen-6-one compounds which are useful as pharmaceutical compositions.



**1 -(DIMETHYLAMINO)ETHYL-SUBSTITUTED 6H-BENZO[C]CHROMEN-6-ONES
AGAINST SENILE DEMENTIA**

This invention relates to novel ($\pm$)1-(Dimethylamino)ethyl substituted 6H-benzo[c]chromen-6-one compounds which are useful as pharmaceutical compositions. This invention further relates to pharmaceutical compositions having benefit in the therapy for the senile dementia, such as Alzheimer senile dementia.

Senile dementia, in particular the Alzheimer senile dementia, has devastating effects on life quality of patients and their relatives. The socioeconomical burden resulting in due to the absolute need for a comprehensive medicare for sufferers of dementia completely presents the dementia accompanying diseases, in particular the Alzheimer's disease, one of the most important health issues of the new millennium awaiting new medicinal alternatives. Therefore, there is a certain need for new medications in the treatment of various forms of dementia, in particular the Alzheimer senile dementia.

Numerous targets, including the β -amyloid formation and hydrolysis cascade, several neurotransmitter formation and hydrolysis pathways, mitochondrial targets and others, have all been examined so far for the treatment of dementia, although only one of them, the cholinergic hypothesis, has been still the only validated pharmaceutical approach in the treatment of the symptoms of dementia, in particular the Alzheimer senile dementia, since, beside the NMDA receptor antagonist drug, memantine, the currently prescribed drugs (i.e., donepezil, galantamine, and rivastigmine), all belong to the acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE) inhibitor class.

Beginning from the discovery of the importance of acetylcholine function in cognitive abilities, including the social lives, natural habits, behaviors, personal characteristics, the mental processes such as interaction (i.e., understanding, speaking, observation) with the environment, attention, problem-solving, remembering, and reminding,

acetylcholine-acting receptors and acetylcholine hydrolyzing enzymes have attracted the attention for the development of drugs having beneficiary effects in the relief of symptoms of dementia, particularly, the Alzheimer senile dementia. These attempts have contributed to the development of ACHE and BCHE inhibitor compounds (i.e.,
5 tacrine, donepezil, rivastigmine, and galantamine).

Unfortunately, the number of these drugs is quite a few, and there are not too many alternatives. In fact, due to the serious hepatotoxic effects of tacrine, there are only 3 drugs on the market in the ACHE inhibitor class. Therefore, there is definitely a need for more alternatives in this class of compounds.

10 In addition, the clinical efficiency of these drugs shows great variance among patients. Furthermore, their benefit is limited with time which means less beneficiary effect is seen with these drugs after sometime following the starting of the treatment. This also indicates the need for new drugs that might possess different characteristics in terms of the prevention of cognitive decline as well as the
15 conservation of the cognitive status from getting worse in a longer period of treatment.


Regarding the inhibitory potential of ACHE and BCHE inhibitor drugs currently prescribed on the market (i.e., donepezil, rivastigmine, and galantamine), these drugs have quite different characteristics in terms of the inhibition of the two
20 enzymes. First of all, galantamine and donepezil are ACHE selective inhibitors, while rivastigmine appear to possess BCHE selectivity. In addition, they have quite distinctive IC_{50} values for the inhibition of ACHE and BCHE enzymes. For instance, donepezil has an IC_{50} for ACHE at a very low nM level in comparison to the IC_{50} of galantamine for ACHE which is close to 1 μ M level. The potential of rivastigmine to
25 inhibit both enzymes is quite different, since the IC_{50} of this drug for both enzymes are above 10 μ M level, although this drug has selectivity for BCHE. This definitely indicates the need of novel medicines having the potential to inhibit the both enzymes with different characteristics including less selectivity.

By the present invention an intensive and extensive investigation on 6H-benzo[c]chromen-6-one compounds have been performed and surprisingly found out that the ($\pm$)-1-(Dimethylamino)ethyl substituted 6H-benzo[c]chromen-6-one compounds have benefit in the therapy for the senile dementia, such as the Alzheimer senile dementia.

Hydroxylated 6H-benzo[c]chromen-6-one compounds, also referred to as urolithins, are metabolites produced by human colonic microflora following the digestion of most of the berries, walnut, and pomegranate. These compounds are not potential inhibitors of ACHE and BCHE enzymes in comparison to the current ACHE and BCHE inhibitor drugs (i.e., donepezil, rivastigmine, and galantamine). Therefore, urolithins have no use in the treatment of dementia, particularly the Alzheimer senile dementia, via the employment of the cholinergic hypothesis that involves the inhibition of ACHE and BCHE enzymes. Furthermore, urolithins are not drugs used in the treatment of dementia, particularly in Alzheimer senile dementia.

By this research subjected to the invention, surprisingly found that these xenobiotics can be converted to potent ACHE and BCHE inhibitors that have activity comparable to the current ACHE and BCHE inhibitor drugs (i.e., donepezil, rivastigmine, and galantamine).

Thus according to the present invention there is now provided the compounds of general formula I or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer



Formula I

wherein;


R₁ is -CH(CH₃)N(CH₃)₂ in racemic form or a single enantiomer;

R₂ is selected from -H, -OH, -OCH₃ or -OCON(CH₃)(C₂H₅);

R₃ is selected from -H, a halogen, an alkyl, or an alkoxy group and can be in any position

and positions of R₁ and R₂ are interchangeable.

In a preferred embodiment of the present invention compounds of general formula II or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer are provided;



Formula II

wherein;

R₁ is -CH(CH₃)N(CH₃)₂ in racemic form or a single enantiomer;

R₂ is selected from -H, -OH, -OCH₃ or -OCON(CH₃)(C₂H₅);

R₃ is H;

5 and positions of R₁ and R₂ are interchangeable.

Preferable compounds of the invention bearing the formula II structure include:

(R)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one.

(S)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one.

(R)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one.

10 (S)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one.

(R)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one.

(S)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one.

(R)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one.

(S)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one.

15 (R)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one.

(S)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one.

(R)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl-ethyl(methyl)carbamate.

(S)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl-ethyl(methyl)carbamate.
20


(R)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl
ethyl(methyl)carbamate.

(S)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl
ethyl(methyl)carbamate.

- 5 In addition, the present invention provides a therapeutically composition which comprises a pharmacologically effective amount of the compound having the formula II or pharmacologically acceptable salt thereof and a pharmacologically acceptable carrier and then a method for preventing and treating a disease due to acetylcholinesterase or butyrylcholinesterase activity by administering to a human
- 10 patient the compound having the formula I or pharmacologically acceptable salts thereof. Furthermore, the enantiomers of the compounds of the present invention described in Formula I provides a therapeutically composition alone or in racemic mixtures which comprises a pharmacologically effective amount of the compound or pharmacologically acceptable salt thereof and a pharmacologically acceptable carrier
- 15 and then a method for preventing and treating a disease due to acetylcholinesterase or butyrylcholinesterase activity by administering to a human patient.

The compounds of the present invention may be prepared by various processes.

A process for the preparation of formula II or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer,



Formula II

wherein;

R_1 is $-\text{CH}(\text{CH}_3)\text{N}(\text{CH}_3)_2$ in racemic form or a single enantiomer;


R_2 is selected from $-\text{H}$, $-\text{OH}$, $-\text{OCH}_3$ or $-\text{OCON}(\text{CH}_3)(\text{C}_2\text{H}_5)$;

R_3 is H ;

5 and positions of R_1 and R_2 are interchangeable;

comprises the steps where (1-(dimethylamino)ethyl)-substituted-phenol compound (formula III) in racemic form or a single enantiomer,


formula III,



Formula III

wherein R_4 is selected from $-\text{H}$ or $-\text{OCH}_3$;


is reacted with a 2-halobenzoic acid compound, in the presence of polyphosphoric acid to form an ester intermediate of formula IV,



Formula IV

wherein R_4 is same as described above, and X is a halogen,

and formula IV in racemic form or a single enantiomer, is reacted with $\text{PdCl}_2(\text{PPh}_3)_2$ in the presence of NaOAc in dimethylacetamide to obtain the compound of formula V



Formula V

wherein R_1 and R_4 are as described above;


treatment of formula V with a hydrolyzing agent to obtain formula II wherein R_2 is OH;

and treatment of formula V with a carbomoyl halide compound to obtain formula II wherein R_2 is $-\text{OCON}(\text{CH}_3)(\text{C}_2\text{H}_5)$.

- 10 Representative examples for the preparation of the compounds having the formula II are described below:

Example I

(±)-3-(1-(dimethylamino)ethyl)phenol




A mixture of 27.23 gram 3-hydroxyacetophenone (0.2 mol), 3.60 gram dimethylamine hydrochloride (0.4 mol), 10 gram activated molecular sieve (3Å) and 10 gram dry MgSO_4 is refluxed in dry methanol for 1-2 hours. Then, 18.85 gram NaCNBH_3 is added to reaction mixture and the mixture is refluxed for additional 18-20 hours. After

hot filtration of reaction mixture, methanol is distilled out under vacuum and the residue thus obtained is dissolved in water (250 mL). The content is acidified with conc. HCl to pH 1 and extracted with ethyl acetate (3x100 mL). The aqueous solution is basified to pH 8-9 using $\text{NaHCO}_{3(s)}$ and extracted with ethyl acetate (5x100 mL). Combined ethyl acetate extracts are washed with water dried over MgSO_4 and concentrated under reduced pressure to give thick oil. This oil is dissolved in isopropyl ether (120 mL) under heating and allowed to cool to 0 °C. The crystalline solid obtained is filtered at the Buchner funnel under vacuum and dried in oven at 60 °C to give the product as a light yellow crystalline solid. Yield obtained: 56.0%. Purity by HPLC: 99%. Mass spectrometry: peak at m/z 166 ($M+1$)⁺. ¹H-NMR data in CD_3OD : δ 1.34 (d, 3H), 2.17 (s, 6H), 3.22 (q, 1H), 6.63-6.68 (m, 1H), 6.69-6.79 (m, 2H), 7.10 (t, 1H).

Example II

(±)-3-(1-(dimethylamino)ethyl)phenyl 2-bromobenzoate




A mixture of 1.65 gram (±)-3-(1-(dimethylamino)ethyl)phenol (10.0 mmol) and 2.2
5 gram 2-bromobenzoic acid (11.0 mmol) is heated in polyphosphoric acid at 80°C for
10-15 minutes. After complete disappearance of aminophenol derivative, checked by
TLC, the reaction vessel put into the ice-bath. Then, 100 mL ethylacetate and 100
mL water are added to reaction mixture respectively and pH of the content is
adjusted to 8-9 using $\text{NaHCO}_{3(s)}$. Organic phase is separated from aqueous phase
10 and then resulted water phase is extracted with ethyl acetate (3x100 mL). Combined
ethyl acetate extracts are washed with water dried over MgSO_4 and concentrated
under reduced pressure to give oily ester product. Yield obtained: 78.0 %. Mass
spectrometry: peak at m/z 348 ($M+1$)⁺. ¹H NMR (300 MHz, CDCl_3 , ppm): δ 1.36 (d,

3H), 2.17 (s, 6H), 3.26 (q, 1H), 7.04-7.21 (m, 3H), 7.26-7.41 (m, 3H), 7.63-7.70 (m, 1H), 7.91-7.99 (m, 1H).

Example III

FAR-02-2RS

5 *(±)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one*



To a solution of *(±)-3-(1-(dimethylamino)ethyl)phenyl 2-bromobenzoate* (1.006 gram, 4.05 mmol) in 35 mL of dry DMA, NaOAc (664 mg, 8.1 mmol) and $\text{PdCl}_2(\text{PPh}_3)_2$ (284 mg, 0.405 mmol) were added at 80 °C. After stirring the reaction mixture at 130 °C for 15-16 h, the solvent was evaporated under reduced pressure. The content is acidified with 1 N HCl (200 mL) and extracted with ethyl acetate (3 x 75 mL). The aqueous solution is basified to pH 8-9 using $\text{NaHCO}_{3(s)}$ and extracted with ethyl acetate (5x100 mL). Combined ethyl acetate extracts are dried over MgSO_4 and concentrated under reduced pressure to give yellow thick oil. Column chromatography on silica gel employing acetone gives desired benzo[c]chromen-6-one derivative (526 mg, 68.0%).

Example IV


(±)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one hydrochloride

2.0 Gram (7.49 mmol) *3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one* (free base) dissolved in dry acetone (10 mL) is filtrated from 0,45 μm filter. HCl gas is passed through the obtained acetone solution until salt precipitation takes place. The content is mixed for additional 1 hour and then filtrated. The retentate is dried at 40°C

under vacuum. Yield obtained: 81.0 %, HPLC purity: 99.90%, HRMS(ESI) $C_{17}H_{18}NO_2$ calcd 268.1338 (M+1)⁺, found 268.1330, DSC: 235.40 °C, ¹H NMR (300 MHz, DMSO, ppm): δ 1.67 (d, 3H), 2.52 (s, 3H), 2.72 (s, 3H), 4.56 (q, 1H), 7.60-7.73 (m, 3H), 7.94 (dt, 1H), 8.22 (dd, 1H), 8.39-8.49 (m, 2H), 11.40 (brs, 1H).

5 Example V

(S)-3-(1-(dimethylamino)ethyl)phenyl 2-bromobenzoate




The desired ester derivative is synthesized according to procedure given in Example II. Yield obtained: 78.0 %. Mass spectrometry: peak at m/z 348 (m+1). ¹H NMR (300 MHz, CDCl₃, ppm): δ 1.36 (d, 3H), 2.17 (s, 6H), 3.26 (q, 1H), 7.04-7.21 (m, 3H), 7.26-7.41 (m, 3H), 7.63-7.70 (m, 1H), 7.91-7.99 (m, 1H).

Example VI

FAR-02-2S

(S)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one



The target molecule is synthesized according to procedure given in Example III. Yield obtained: 66.0 %

Example VII


(S)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one.HCl

The desired salt form is synthesized according to procedure given in Example IV.

Yield obtained: 83.0 %. HPLC purity: 99.95%, HRMS(ESI) $C_{17}H_{18}NO_2$ calcd
5 268.1338 ($M+1$)⁺, found 268.1341, DSC: 254.13 °C, ¹H NMR (300 MHz, DMSO, ppm): δ 1.66 (d, 3H), 2.51 (d, 3H), 2.72 (d, 3H), 4.50-4.62 (m, 1H), 7.59-7.74 (m, 3H), 7.92 (dt, 1H), 8.22 (dd, 1H), 8.37-8.49 (m, 2H), 11.36 (brs, 1H).

Example VIII

1-(3-hydroxy-5-methoxyphenyl)ethanone




Procedure A: 6.2 gram NaOH (0.150 mol) is dissolved in 125 mL water. 25 gram 3,5-dihydroxyacetophenone (0.160 mol) is weighted in 250 mL round bottom flask and previously prepared NaOH solution is added to the flask. After complete dissolution of acetophenone derivative in basic aqueous media, the reaction mixture is cooled to
15 0-10 °C. Then, 19.5 gram DMS (0.156 mol) is added to reaction flask dropwise. The content is mixed at ambient temperature for one hour, and then it is heated at 50 °C for two hours. To separate 3,5-dimethoxyacetophenone impurity, pH of medium is adjusted to 14 with NaOH pellet and this solution is extracted with EtOAc (3x50 mL). The alkali solution is acidified with conc HCl to pH 1 and extracted with ethyl acetate
20 (3x75 mL). Combined ethyl acetate extracts are dried over $MgSO_4$ and concentrated under reduced pressure to give mixture of 3,5-dihydroxyacetophenone and 1-(3-hydroxy-5-methoxyphenyl)ethanone. To the mixture, 50 mL acetone and 25 gram $NaOH_{(s)}$ is added. When, 8-10 mL cold water is put into the reaction flask slowly, sodium salt of 3,5-dihydroxyacetophenone is precipitated. The liquid part of the

content is decanted to another round bottom flask. The solid part is washed with acetone (3x15 mL). Combined acetone parts concentrated under reduced pressure to give 1-(3-hydroxy-5-methoxyphenyl)ethanone as off white solid. Yield obtained: 56.2 %. Mass spectrometry: peak at m/z 166 ($m+1$). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 2.56 (s, 3H), 3.79 (s, 3H), 6.62-6.67 (m, 2H), 7.01-7.05 (m, 1H), 7.07-7.11 (m, 1H).

Procedure B: 11.36 mL NEt_3 (82.14 mmol) is added to 137 mL water. 25 gram 3,5-dihydroxyacetophenone (0.160 mol) is weighed in 250 mL round bottom flask and previously prepared NEt_3 solution is added to the flask. The reaction mixture is cooled to 0-10 °C. Then, 7.78 mL DMS (82.14 mol) is added to reaction flask dropwise. The content is mixed at ambient temperature for 4 hours. After the reaction mixture is cooled 0-5 °C, the content is filtrated to remove undissolved 3,5-dihydroxyacetophenone. pH of filtrate is adjusted to 1 with conc. HCl and extracted with EtOAc (3x50 mL). Combined ethyl acetate extracts are dried over MgSO_4 and concentrated under reduced pressure to give mixture of 3,5-dihydroxyacetophenone and 1-(3-hydroxy-5-methoxyphenyl)ethanone. To the mixture, 50 mL acetone and 25 gram $\text{NaOH}_{(s)}$ is added. When, 8-10 mL cold water is put into the reaction flask slowly, sodium salt of 3,5-dihydroxyacetophenone is precipitated. The liquid part of the content is decanted to another round bottom flask. The solid part is washed with acetone (3x15 mL). Combined acetone parts concentrated under reduced pressure to give 1-(3-hydroxy-5-methoxyphenyl)ethanone as off white solid. Yield obtained: 44.7 %, Mass spectrometry: peak at m/z 166 ($M+1$) $^+$. ^1H NMR (300 MHz, CDCl_3 , ppm): δ 2.56 (s, 3H), 3.79 (s, 3H), 6.62-6.67 (m, 2H), 7.01-7.05 (m, 1H), 7.07-7.11 (m, 1H).

Example IX


(±)-3-(1-(dimethylamino)ethyl)-5-methoxyphenol



The desired aminophenol derivative is synthesized according to procedure given in Example I. Yield obtained: 60.6 %. Mass spectrometry: peak at m/z 196 ($M+1$)⁺. ¹H NMR (300 MHz, CDCl₃, ppm): δ 1.29 (d, 3H), 2.13 (s, 6H), 3.15 (q, 1H), 3.61 (s, 3H), 6.21 (t, 1H), 6.24-6.27 (m, 1H), 6.29-6.31 (m, 1H), 8.32 (brs, 1H).

Example X

(±)-3-(1-(dimethylamino)ethyl)-5-methoxyphenyl 2-bromobenzoate




The desired ester derivative is synthesized according to procedure given in Example II. Yield obtained: 70.2 %. Mass spectrometry: peak at m/z 378 ($M+1$)⁺. ¹H NMR (300 MHz, CDCl₃, ppm): δ 1.33 (d, 3H), 2.19 (s, 6H), 3.23 (q, 1H), 3.75 (s, 3H), 6.64 (t, 1H), 6.75 (d, 2H), 7.32-7.39 (m, 2H), 7.64-7.69 (m, 1H), 7.92-7.97 (m, 1H).

Example XI

FAR-01-2

(±)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one



- 5 The target molecule is synthesized according to procedure given in Example III. Yield obtained: 46.2 %

Example XII

(±)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one hydrochloride


The desired salt form is synthesized according to procedure given in Example IV.

- 10 Yield obtained: 81.3%. HPLC purity: 99.40%, HRMS(ESI) $C_{18}H_{20}NO_3$ calcd 298.1443 ($M+1$)⁺, found 298.1433, DSC: 247.81 °C, ¹H NMR (300 MHz, DMSO, ppm): δ 1.68 (d, 3H), 2.56 (d, 3H), 2.76 (d, 3H), 4.07 (s, 3H), 4.51 (q, 1H), 7.27 (d, 1H), 7.47 (s, 1H), 7.65 (dt, 1H), 7.90 (dt, 1H), 8.25 (dd, 1H), 8.93 (d, 1H), 11.41 (brs, 1H).

Example XIII

- 15 FAR-01-1

(±)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one



The target molecule is synthesized according to procedure given in Example III. Yield obtained: 14.2 %

Example XIV


(±)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one hydrochloride

- 5 The desired salt form is synthesized according to procedure given in Example IV. Yield obtained: 83.7 %, HPLC purity: 99.90%, HRMS(ESI) $C_{18}H_{20}NO_3$ calcd 298.1443 (M+1)⁺, found 298.1431, DSC: 110.42 °C, ¹H NMR (300 MHz, CD₃OD, ppm): δ 1.54 (d, 3H), 2.18 (s, 6H), 3.86 (s, 3H), 4.15 (q, 1H), 6.81 (d, 1H), 7.24 (d, 1H), 7.53 (dt, 1H), 7.82 (dt, 1H), 8.20 (brs, 1H), 8.28 (dd, 1H).

10 EXAMPLE XV

FAR-01-2OH

(±)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one



- To (±)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one (4.60 gram, 15.47 mmol) is added 48% aqueous HBr (190 mL) at room temperature. The mixture was heated at 130 °C for 20-24 hours. After cooling, the aqueous solution is basified to pH 8-9 using NaHCO_{3(s)} and extracted with CH₂Cl₂ (4x50 mL). Combined CH₂Cl₂ extracts are dried over MgSO₄ and concentrated under reduced pressure to give yellow-brown oil. Column chromatography on silica gel employing acetone gave
20 desired benzo[c]chromen-6-one derivative (1.37gram, 31.0%).

Example XVI


(±)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one hydrochloride

1.37 gram (4.8 mmol) (±)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one (free base) dissolved in 30 mL dry metanol:asetone (1:3) is filtrated from 0.45
5 µm filtre. HCl gas is passed through the obtained metanol-asetone solution. Liquid part is concentrated under reduced pressure to give yellow oil. When 10 ml dry asetone is added to resulted oil, HCl salt form of 3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one is precipitated. The content is mixed for 1 hour and then filtrated. The residue is dried at 40 °C under vacuum. Yield obtained: 79.3
10 %. HPLC purity: 99.82%, HRMS(ESI) C₁₇H₁₈NO₃ calcd 284.1287 (M+1)⁺, found 284.1293, DSC: 253.54 °C ¹H NMR (300 MHz, DMSO, ppm): δ 1.62 (d, 3H), 2.54 (s, 3H), 2.75 (s, 3H), 4.43 (q, 1H), 7.06 (s, 1H), 7.23 (s, 1H), 7.62 (t, 1H), 7.90 (dt, 1H), 8.24 (d, 1H), 9.09 (d, 1H), 11.07 (brs, 1H), 11.55 (s, 1H).

EXAMPLE XVII

15 FAR-01-1OH

(±)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one



To (±)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one (1.49 gram, 5.0 mmol) is added 48% aqueous HBr (62mL) at room temperature. The mixture was
20 heated at 120 °C for 4 hours. After cooling, the aqueous solution is basified to pH 8-9 using NaHCO_{3(s)} and extracted with CH₂Cl₂ (4x40 mL). Combined CH₂Cl₂ extracts are dried over MgSO₄ and concentrated under reduced pressure to give yellow solid (1.20 gram, 84.5%).

EXAMPLE XVIII

(±)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one.HCl

The desired salt form is synthesized according to procedure given in Example IV.


Yield obtained: 86.0 %. HPLC purity: 99.07%, HRMS(ESI) $C_{17}H_{18}NO_3$ calcd

284.1287 ($M+1$)⁺, found 284.1289, DSC: 217.01°C, ¹H NMR (300 MHz, CD₃OD, ppm): δ 1.50 (d, 3H), 2.17 (s, 6H), 4.13 (q, 1H), 6.62 (d, 1H), 7.09 (s, 1H), 7.48 (t, 1H), 7.78 (dt, 1H), 8.15 (brs, 1H), 8.25 (dd, 1H).

Example XIX

FAR-01-2CA

(±)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl ethyl(methyl)carbamate



960 mg (±)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one (3.00 mmol) and 547.40 mg carbamoyl chloride (4.30 mmol) is mixed in pyridine (18 mL) at ambient temperature for 18-20 hours. Pyridine is concentrated under reduced pressure to give yellow-brown oil. Then pH is adjusted to 8-9 using saturated NaHCO₃ and extracted with CH₂Cl₂ (4x50 mL). Combined CH₂Cl₂ extracts are dried over MgSO₄ and concentrated under reduced pressure to give yellow thick oil. Column chromatography on silica gel employing acetone gives desired benzo[c]chromen-6-one derivative (1.04 gram, 95.0%).

EXAMPLE XX


(±)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl
ethyl(methyl)carbamate hydrochloride

1,00 gram (2,7 mmol) (±)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl
5 ethyl(methyl)carbamate (free base) dissolved in 30 mL dry asetone:heptane (1:3) is
filtrated from 0,45 µm filtre. HCl gas is passed through the obtained asetone-heptane
solution, untill salt precipitation takes place. The content is mixed for 2 hours and
then filtrated. The filtrand is dried at 40 °C under vacuum. Yield obtained: 96.3 %.
HPLC purity: 99.16%, HRMS(ESI) C₂₁H₂₅N₂O₄ calcd 369.1814 (M+1)⁺, found
10 369.1825, DSC: 256.35 °C, ¹H NMR (300 MHz, DMSO, ppm): δ 1.07-1.35 (m, 3H),
1.67 (d, 3H), 2.54 (d, 3H), 2.71 (d, 3H), 3.08 (d, 3H), 3.28-3.68 (m, 2H), 4.57 (q, 1H),
7.42 (s, 1H), 7.65-7.77 (m, 2H), 7.91-8.02 (m, 1H), 8.27-8.42 (m, 2H), 11.37 (brs,
1H).

Example XXI

15 FAR-01-1CA

(±)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl
ethyl(methyl)carbamate



660 mg (±)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one (2,33
20 mmol) and 424,76 mg carbamoyl chloride (3.49 mmol) is mixed in pyridine (16 mL) at
ambient temperature for 17-19 hours. Pyridine is concentrated under reduced
pressure to give yellow-brown oil. Then pH is adjusted to 8-9 using saturated

NaHCO₃ and extracted with CH₂Cl₂ (4x50 mL). Combined CH₂Cl₂ extracts are dried over MgSO₄ and concentrated under reduced pressure to give yellow thick oil. Column chromatography on silica gel (Asetone: Dichlorometan; 2:1) gave desired benzo[c]chromen-6-one derivative (511 mg, 60.0%).

5 EXAMPLE XXII

(±)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl
ethyl(methyl)carbamate hydrochloride

511 mg (1.4 mmol) (±)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl
ethyl(methyl)carbamate (free base) dissolved in 30 mL dry eter:asetone (1:3) is
10 filtrated from 0.45 µm filtre. HCl gas is passed through the obtained eter-asetone
solution, untill salt precipitation takes place. The content is mixed for 2 hours and
then filtrated. The filtrand is dried at 40 °C under vacuum. Yield obtained: 71.7 %.
HPLC purity: 99.62%, HRMS(ESI) C₂₁H₂₅N₂O₄ calcd 369.1814 (M+1)⁺, found
369.1808, DSC: 127.9°C, ¹H NMR (300 MHz, CD₃OD, ppm): δ 1.13-1.31 (m, 3H),
15 1.67 (d, 3H), 2.33 (s, 6H), 3.04 (d, 3H), 3.34-3.57 (m, 2H), 4.48 (brs, 1H), 7.13 (s,
1H), 7.43 (d, 1H), 7.63 (dt, 1H), 7.89 (dt, 1H), 8.16 (brs, 1H), 8.33 (dd, 1H).

The compounds of the present invention concomitant with the pharmaceutical salts
thereof represented by the general formula II, including the each enantiomer, are
useful in the treatment of various kinds of senile dementia, in particular Alzheimer's
20 Disease accompanying senile dementia. Related pharmacological experimental data
are described.

Experimental (Pharmacology)

The potential of the compounds of the present invention to inhibit
acetylcholinesterase and butyrylcholinesterase enzymes were tested according to
25 the method of Ellman et.al. (i.e., Ellman, G. L., Courtney, K. D., Andres, V., and
Featherstone, R. M., *Biochem. Pharmacol.*, **1961**, 7, 88-95).

Human recombinant acetylcholinesterase and human recombinant butyrylcholinesterase were employed. Each reaction mixture contained the enzyme (either ACHE or BCHE) solution, DTNB and sample in Tris HCl buffer solution. The reactions were initiated by the addition of the substrate (either acetylthiocholine iodide or butyrylthiocholine iodide, respectively for ACHE and BCHE enzymes). The enzyme catalyzed formation of the yellow color was measured at 412 nm in terms of the calculation of enzyme activity concomitant to the presence of an inhibitor activity. The acetylcholinesterase and butyrylcholinesterase inhibitory activity of each sample was expressed in terms of inhibitory concentration 50% (IC₅₀).

Representative examples are shown in Table I:

Compound	ACHE Inhibitory Activity IC ₅₀ (μM)	BCHE Inhibitory Activity IC ₅₀ (μM)	Example No.
FAR-02-2RS	10.9	17.9	III
FAR-02-2S	7.9	16.2	VI
FAR-01-2	2.8	21.1	XI
FAR-01-1	15.1	24.7	XIII
FAR-01-2OH	18.9	4.2	XV
FAR-01-1OH	33.1	>40	XVII
FAR-01-2CA	40.0	12.7	XIX
FAR-01-1CA	>40	8.5	XXI
Rivastigmine	35,2	11,0	-
Galantamine	0,7	21,9	-
Donepezil	0,008	7,1	-

In general, the compounds of the present invention displayed strong potential for the inhibition of both ACHE and BCHE enzymes.

There are several compounds which possess strong inhibition towards BCHE. In comparison to the current drugs (i.e., galantamine, rivastigmine, and donepezil), the compounds such as FAR-01-2OH, FAR-01-2CA, and FAR-01-1CA have exhibited at least comparable and/or better inhibitory potential towards BCHE inhibition.

- 5 Although, the selectivity of the compounds of the present invention seems to be bias for the ACHE enzyme some of the compounds (i.e., FAR-01-2OH, and FAR-01-1CA) possess selectivity to inhibit the BCHE.

The diversity obtained through the different IC_{50} values of the compounds of the present invention makes them alternative promising compounds in the treatment of
10 dementia, particularly the Alzheimer senile dementia.

Experimental (Passive avoidance learning test)

The passive avoidance test evaluates the ability of a rat to learn and memorize. Male Wistar rats, at an age of approximately 2 months, and around 250 g body weight
15 were used. For learning, the rats were placed into the illuminated compartment while the door closed and allowed a habituation phase (30 seconds). Then the door automatically opened and stayed open for 5 minutes experimental time. Two seconds after the rat entering the dark compartment of the apparatus the door closed and after 2 seconds latency an electric stimulus took place lasting for 3 or 6 seconds.
20 The rat stayed in the dark compartment for another 30 seconds delay before it was placed into the home cage.

For testing, the rats were treated with 1 mg/kg (i.p.) of scopolamine, half an hour before the administration of the each test compound. Half an hour after the oral
25 administration of the each compound, the rats were placed into the illuminated compartment with the door closed again for a habituation time of 30 seconds. Following the opening of the door automatically, the time for the rats visiting the dark

box (latency) was measured for 5 minutes. The time difference between the no scopolamine administered group and the only scopolamine administered group was taken as 100% and the effect of each compound of the present invention was calculated accordingly in terms of the percentage antagonism. Each test compound was assessed employing ten animals per dose.

The results are shown Table II:


Compound	Dose (mg/kg)	Reverse (%)	Example No.
FAR-02-2RS	1	70	III
FAR-02-2S	1	71	VI
FAR-01-2	1	71	XI
FAR-01-2OH	1	49	XV
FAR-01-2CA	1	53	XIX
Donepezil	1	52	
Rivastigmine	1	85	

As seen in the Table II, the compounds of the present invention have considerable effect in the test of passive avoidance learning impairment induced by scopolamine.

The results obtained through both the in-vitro acetylcholinesterase and butyrylcholinesterase inhibition tests and the in-vitro passive avoidance test present the compounds of this invention as powerful, promising, and novel compounds effective for various kinds of dementia, particularly the Alzheimer senile dementia.

CLAIMS

1. A compound having the following formula I or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer



Formula I

wherein;


R_1 is $-\text{CH}(\text{CH}_3)\text{N}(\text{CH}_3)_2$ in racemic form or a single enantiomer;

R_2 is selected from $-\text{H}$, $-\text{OH}$, $-\text{OCH}_3$ or $-\text{OCON}(\text{CH}_3)(\text{C}_2\text{H}_5)$;

R_3 is selected from $-\text{H}$, a halogen, an alkyl, or an alkoxy group and can be in any position

and positions of R_1 and R_2 are interchangeable.

2. A compound according to Claim 1 having the following formula II or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer



Formula II

wherein;

R₁ is -CH(CH₃)N(CH₃)₂ in racemic form or a single enantiomer;

5 R₂ is selected from -H, -OH, -OCH₃ or -OCON(CH₃)(C₂H₅);

R₃ is H;

and positions of R₁ and R₂ are interchangeable.

3. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one.

10

4. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one.

5. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one.

15

6. The compound according to Claim 1 or a pharmaceutical acceptable salt thereof, which is (S)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one.

20

7. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one.

5 8. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one.

10 9. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one.

15 10. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one.

20 11. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one.

12. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one.

25 13. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl ethyl(methyl)carbamate.

14. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl ethyl(methyl)carbamate.

5 15. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl ethyl(methyl)carbamate.

10 16. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl ethyl(methyl)carbamate.

15 17. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof for preparing a medicament for the treatment of a disease due to acetylcholinesterase and/or butyrylcholinesterase activity.


20 18. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof for the treatment of senile dementia.

19. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof for the treatment of the Alzheimer dementia.

25 20. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof for the treatment of any central nervous system disease.

21. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof, and a pharmaceutical acceptable carrier.

5 22. A process for the preparation of formula II or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer ,



Formula II

wherein;

10 R₁ is -CH(CH₃)N(CH₃)₂ in racemic form or a single enantiomer;


R₂ is selected from -H, -OH, -OCH₃ or -OCON(CH₃)(C₂H₅);

R₃ is H;

and positions of R₁ and R₂ are interchangeable;

15 comprises the steps where (1-(dimethylamino)ethyl)-substituted-phenol compound (formula III) in racemic form or a single enantiomer;


formula III



Formula III

wherein R_4 is selected from $-H$ or $-OCH_3$;


is reacted with a 2-halobenzoic acid compound, in the presence of
 5 polyphosphoric acid to form an ester intermediate of formula IV,



Formula IV

wherein R_4 is same as described above, and X is a halogen,

and formula IV in racemic form or a single enantiomer, is reacted with
 10 $PdCl_2(PPh_3)_2$ in the presence of $NaOAc$ in dimethylacetamide to obtain the
 compound of formula V,



Formula V

wherein R_1 and R_4 are as described above;

treatment of formula V with a hydrolyzing agent to obtain formula II wherein R_2 is OH;

and treatment of formula V with a carbomoyl halide compound to obtain
5 formula II wherein R_2 is $-\text{OCON}(\text{CH}_3)(\text{C}_2\text{H}_5)$.

23. (+)-3-(1-(dimethylamino)ethyl)phenyl 2-halobenzoate.

24. (-)-3-(1-(dimethylamino)ethyl)phenyl 2-halobenzoate.

25. ($\pm$)-3-(1-(dimethylamino)ethyl)phenyl 2-halobenzoate.

26. (+)-3-(1-(dimethylamino)ethyl)-5-methoxyphenyl 2-halobenzoate.


27. (-)-3-(1-(dimethylamino)ethyl)-5-methoxyphenyl 2-halobenzoate.

28. ($\pm$)-3-(1-(dimethylamino)ethyl)-5-methoxyphenyl 2-halobenzoate.

AMENDED CLAIMS

received by the International Bureau on 15 July 2014 (15.07.2014)

1. A compound having the following formula I or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer



Formula I

wherein;


R₁ is -CH(CH₃)N(CH₃)₂ in racemic form or a single enantiomer;

R₂ is selected from -H, -OH, -OCH₃ or -OCON(CH₃)(C₂H₅);

R₃ is selected from -H, a halogen, an alkyl, or an alkoxy group and can be in any position

and positions of R₁ and R₂ are interchangeable.

2. A compound according to Claim 1 having the following formula II or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer



Formula II

wherein;

R_1 is $-\text{CH}(\text{CH}_3)\text{N}(\text{CH}_3)_2$ in racemic form or a single enantiomer;

5 R_2 is selected from $-\text{H}$, $-\text{OH}$, $-\text{OCH}_3$ or $-\text{OCON}(\text{CH}_3)(\text{C}_2\text{H}_5)$;

R_3 is H ;

and positions of R_1 and R_2 are interchangeable.

3. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one.

10

4. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-3-(1-(dimethylamino)ethyl)-6H-benzo[c]chromen-6-one.

5. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one.

15


6. The compound according to Claim 1 or a pharmaceutical acceptable salt thereof, which is (S)-3-(1-(dimethylamino)ethyl)-1-methoxy-6H-benzo[c]chromen-6-one.

20

7. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one.
- 5 8. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-1-(1-(dimethylamino)ethyl)-3-methoxy-6H-benzo[c]chromen-6-one.
9. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one.
- 10 10. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-3-(1-(dimethylamino)ethyl)-1-hydroxy-6H-benzo[c]chromen-6-one.
- 15 11. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one.
- 20 12. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-1-(1-(dimethylamino)ethyl)-3-hydroxy-6H-benzo[c]chromen-6-one.
- 25 13. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl ethyl(methyl)carbamate.

14. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-3-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-1-yl ethyl(methyl)carbamate.
- 5 15. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (R)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl ethyl(methyl)carbamate.
- 10 16. The compound according to Claim 1, 2 or a pharmaceutical acceptable salt thereof, which is (S)-1-(1-(dimethylamino)ethyl)-6-oxo-6H-benzo[c]chromen-3-yl ethyl(methyl)carbamate.
- 15 17. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof for preparing a medicament for the treatment of a disease due to acetylcholinesterase and/or butyrylcholinesterase activity selected from senile dementia, Alzheimer dementia and any central nervous system disease
- 20 18. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof for the treatment of senile dementia.
- 25 19. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof for the treatment of the Alzheimer dementia.
20. The use of a compound having the formula I according to the Claim 1 or a pharmaceutical acceptable salt thereof for the treatment of any central nervous system disease.

21. A process for the preparation of formula II or a pharmaceutical acceptable salt thereof as a racemic mixture or a single enantiomer ,



5

Formula II

wherein;

R₁ is -CH(CH₃)N(CH₃)₂ in racemic form or a single enantiomer;

R₂ is selected from -H, -OH, -OCH₃ or -OCON(CH₃)(C₂H₅);


R₃ is H;

10

and positions of R₁ and R₂ are interchangeable;

comprises the steps where (1-(dimethylamino)ethyl)-substituted-phenol compound (formula III) in racemic form or a single enantiomer;

formula III




15

Formula III

wherein R_4 is selected from $-H$ or $-OCH_3$;

is reacted with a 2-halobenzoic acid compound, in the presence of polyphosphoric acid to form an ester intermediate of formula IV,




5

Formula IV

wherein R_4 is same as described above, and X is a halogen,

and formula IV in racemic form or a single enantiomer, is reacted with $PdCl_2(PPh_3)_2$ in the presence of NaOAc in dimethylacetamide to obtain the compound of formula V,



10

Formula V

wherein R_1 and R_4 are as described above;

treatment of formula V with a hydrolyzing agent to obtain formula II wherein R_2 is OH;

15

and treatment of formula V with a carbomoyl halide compound to obtain formula II wherein R_2 is $-OCON(CH_3)(C_2H_5)$.

22. (+)-3-(1-(dimethylamino)ethyl)phenyl 2-halobenzoate.

23. (-)-3-(1-(dimethylamino)ethyl)phenyl 2-halobenzoate.

5

24. (±)-3-(1-(dimethylamino)ethyl)phenyl 2-halobenzoate.

25. (+)-3-(1-(dimethylamino)ethyl)-5-methoxyphenyl 2-halobenzoate.

10

26. (-)-3-(1-(dimethylamino)ethyl)-5-methoxyphenyl 2-halobenzoate.

27. (±)-3-(1-(dimethylamino)ethyl)-5-methoxyphenyl 2-halobenzoate.

15

INTERNATIONAL SEARCH REPORT

International application No
PCT/TR2014/000028

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D311/80 A61K31/352 A61P25/28
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EP0-Internal, WPI Data, BEILSTEIN Data, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LEONARDO PISANI ET AL: "Design, Synthesis, and Biological Evaluation of Coumarin Derivatives Tethered to an Edrophonium-like Fragment as Highly Potent and Selective Dual Binding Site Acetylcholinesterase Inhibitors", CHEMMEDCHEM, vol. 5, no. 9, 3 September 2010 (2010-09-03), pages 1616-1630, XP055116717, ISSN: 1860-7179, DOI: 10.1002/cmdc.201000210 table 1; compound 10	1-28
A	US 2005/171079 A1 (SCHRIMPF MICHAEL R [US] ET AL) 4 August 2005 (2005-08-04) claim 19; compounds 1119-1140 ----- -/--	1-28

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

8 May 2014

Date of mailing of the international search report

21/05/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Stroeter, Thomas

INTERNATIONAL SEARCH REPORT

International application No

PCT/TR2014/000028

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PIAZZI L ET AL: "3(4-äÄBENZYL(METHYL)AMINOÜMETHYLÜ-PHENYL) -6,7-DIMETHOXY-2H-2-CHROMENONE (AP2238) INHIBITS BOTH ACETYLCHOLINESTERASE AND ACETYLCHOLINESTERASE-INDUCED BETA-AMYLOID AGGREGATION: A DUAL FUNCTION LEAD FOR ALZHEIMER'S DISEASE THERAPY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 46, no. 12, 1 January 2003 (2003-01-01), pages 2279-2282, XP001199895, ISSN: 0022-2623, DOI: 10.1021/JM0340602 compound 4 -----	1-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/TR2014/000028

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2005171079 A1	04-08-2005	CA 2555884 A1	25-08-2005
		EP 1711463 A2	18-10-2006
		EP 2258682 A2	08-12-2010
		JP 2007523899 A	23-08-2007
		US 2005171079 A1	04-08-2005
		WO 2005077899 A2	25-08-2005
